Your browser doesn't support javascript.
Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
Wang, L; Peng, X; Wang, Z-H; Cai, J; Zhou, F-C.
  • Wang L; Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. zfc88@126.com.
Eur Rev Med Pharmacol Sci ; 24(10): 5783-5787, 2020 May.
Article in English | MEDLINE | ID: covidwho-542679
ABSTRACT
In December 2019, Coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China and the rest of the world. COVID-19 is currently a global pandemic. There are cytokine storms in severe COVID-19 patients. Interleukin-6 plays an important role in cytokine storm. Tocilizumab is a blocker of interleukin-6 receptor, which is likely to become an effective drug for patients with severe COVID-19. Here, we reported a case in which tocilizumab was effective for a critical COVID-19 patient.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Monoclonal, Humanized Type of study: Case report Limits: Humans / Male / Middle aged Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2020 Document Type: Article Affiliation country: Eurrev_202005_21372

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Monoclonal, Humanized Type of study: Case report Limits: Humans / Male / Middle aged Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2020 Document Type: Article Affiliation country: Eurrev_202005_21372